{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:31:39Z","timestamp":1794000699566,"version":"4.8.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To date, few studies have carried out a simultaneous determination of multiple pro- and anti-angiogenic factors during liver diseases progression. This study investigated the dynamic change in circulating angiogenic factors in multi-step carcinogenesis and hepatocellular carcinoma (HCC) progression. Serum levels of major pro-angiogenic [Vascular endothelial growth factor (VEGF), Basic fibroblast growth factor (b-FGF)] and anti-angiogenic [Thrombospondin-1 (TSP-1), Endostatin] factors were identified by enzyme-linked immunosorbent assay and correlated with liver diseases progression and outcomes of HCC patients undergoing transarterial chemo-embolization. A total of 240 patients (156 HCC, 37 cirrhosis and 47 chronic hepatitis) were enrolled in this study. While progressing from chronic hepatitis, cirrhosis to HCC, VEGF and b-FGF levels showed a significant change. Particularly, b-FGF yielded the highest AUROC value for a diagnosis of HCC and its distinction from other disease groups. A trend towards increasing VEGF levels was observed from Child-Pugh class A, B to C. VEGF and TSP-1 levels increased with the advance of cancer stage, with a remarkable increase in TSP-1 at an intermediate stage. Pretreatment levels of VEGF, TSP-1, and endostatin independently predicted the overall survival of patients. VEGF and TSP-1 levels correlated with progression-free survival. Our study demonstrated the dynamic angiogenic switch and the roles that individual pro- and anti-angiogenic factors contribute to carcinogenesis and HCC progression during the course of multi-step liver diseases. These imply the future possibility of testing pro- and anti-angiogenic panels as a diagnostic marker and a guide in decision-making about upcoming targeted therapies.<\/jats:p>","DOI":"10.1038\/s41598-019-45537-w","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T06:03:22Z","timestamp":1561356202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression"],"prefix":"10.1038","volume":"9","author":[{"given":"Yu Young","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Woo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-4868","authenticated-orcid":false,"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"45537_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","volume":"41","author":"D Semela","year":"2004","unstructured":"Semela, D. & Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J Hepatol 41, 864\u2013880 (2004).","journal-title":"J Hepatol"},{"key":"45537_CR2","unstructured":"Kerbel, R. S. t. S. R. I., Sunnybrook Health Sciences Centre, a., the Department of Medical Biophysics & Toronto, U. o. Tumor Angiogenesis. The new england and journal of medicine (2008)."},{"key":"45537_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.20193","volume":"39","author":"J Medina","year":"2004","unstructured":"Medina, J., Arroyo, A. G., Sanchez-Madrid, F. & Moreno-Otero, R. Angiogenesis in chronic inflammatory liver disease. Hepatology (Baltimore, Md.) 39, 1185\u20131195 (2004).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"45537_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1478-3231.2010.02369.x","volume":"31","author":"S Coulon","year":"2011","unstructured":"Coulon, S. et al. Angiogenesis in chronic liver disease and its complications. Liver international: official journal of the International Association for the Study of the Liver 31, 146\u2013162 (2011).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"45537_CR5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse, M. A. et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 25, 912\u2013920 (2019).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"45537_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3350\/cmh.2017.0111","volume":"23","author":"EW Lee","year":"2017","unstructured":"Lee, E. W. & Khan, S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Clinical and molecular hepatology 23, 265\u2013272 (2017).","journal-title":"Clinical and molecular hepatology"},{"key":"45537_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","volume":"50","author":"M Fernandez","year":"2009","unstructured":"Fernandez, M. et al. Angiogenesis in liver disease. J Hepatol 50, 604\u2013620 (2009).","journal-title":"J Hepatol"},{"key":"45537_CR8","unstructured":"Young Nyun Park, D. o. P., Yonsei University College of Medicine. Role of Angiogenic Factors during the Hepatocarcinogenesis. Clinical and Molecular Hepatology (2001)."},{"key":"45537_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jnci\/89.3.219","volume":"89","author":"GD Grossfeld","year":"1997","unstructured":"Grossfeld, G. D. et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. 89, 219\u2013227 (1997).","journal-title":"J. Natl. Cancer Inst."},{"key":"45537_CR10","first-page":"3941","volume":"22","author":"K Miyanaga","year":"2002","unstructured":"Miyanaga, K. et al. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res. 22, 3941\u20133948 (2002).","journal-title":"Anticancer Res."},{"key":"45537_CR11","first-page":"3547","volume":"37","author":"H Kashihara","year":"2017","unstructured":"Kashihara, H. et al. Correlation Between Thrombospondin-1 Expression in Non-cancer Tissue and Gastric Carcinogenesis. Anticancer Res. 37, 3547\u20133552 (2017).","journal-title":"Anticancer Res."},{"key":"45537_CR12","doi-asserted-by":"crossref","unstructured":"Rohrs, J. A., Sulistio, C. D. & Finley, S. D. Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue. NPJ Syst Biol Appl 2 (2016).","DOI":"10.1038\/npjsba.2016.30"},{"key":"45537_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00018-007-7486-z","volume":"65","author":"S Kazerounian","year":"2008","unstructured":"Kazerounian, S., Yee, K. O. & Lawler, J. Thrombospondins in cancer. Cell. Mol. Life Sci. 65, 700\u2013712 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"45537_CR14","doi-asserted-by":"publisher","first-page":"11044","DOI":"10.1158\/0008-5472.CAN-05-2617","volume":"65","author":"I Celik","year":"2005","unstructured":"Celik, I. et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65, 11044\u201311050 (2005).","journal-title":"Cancer Res."},{"key":"45537_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","volume":"312","author":"J Folkman","year":"2006","unstructured":"Folkman, J. Antiangiogenesis in cancer therapy\u2013endostatin and its mechanisms of action. Exp Cell Res 312, 594\u2013607 (2006).","journal-title":"Exp Cell Res"},{"key":"45537_CR16","first-page":"43","volume":"1","author":"SJ Coleman","year":"2014","unstructured":"Coleman, S. J., Grose, R. P. & Kocher, H. M. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 1, 43\u201354 (2014).","journal-title":"J Hepatocell Carcinoma"},{"key":"45537_CR17","doi-asserted-by":"crossref","unstructured":"2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver 9, 267\u2013317 (2015).","DOI":"10.5009\/gnl14460"},{"key":"45537_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3350\/cmh.2016.22.1.7","volume":"22","author":"SJ Yu","year":"2016","unstructured":"Yu, S. J. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010\u20132016. Clin Mol Hepatol 22, 7\u201317 (2016).","journal-title":"Clin Mol Hepatol"},{"key":"45537_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 (2010).","journal-title":"Semin. Liver Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45537-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:43:05Z","timestamp":1671255785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45537-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45537"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45537-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9137"}}